Navigation Links
Research presented at 2011 GU Cancers Symposium highlights advances in treatment of prostate cancer
Date:2/16/2011

ALEXANDRIA, Va. New studies on the screening and treatment of genitourinary cancers were released today in advance of the fourth annual Genitourinary Cancers Symposium, being held February 17-19, 2011, at the Orlando World Center Marriott in Orlando, Florida.

The results of three studies were highlighted in a media presscast (press briefing via live webcast):

  • Large screening study shows reduced risk of prostate cancer death for men with low initial PSAs: A large prostate cancer screening study of middle-aged and elderly men showed that an initial Prostate-Specific Antigen (PSA) score of 3.0 ng/ml appears to be an appropriate minimum cut-off level to determine the need for biopsy. Few men in the study with low first-time PSAs below 3.0 developed prostate cancer and died from the disease, and the findings may help better target testing for those at risk.

  • Proficiency in robotic-assisted prostate surgery requires experienced specialists: In a study to determine the surgical learning curve for robotic-assisted laparoscopic radical prostatectomy (RALP) operations, a retrospective analysis of the results of nearly 3,800 procedures showed that it took more than 1,600 prostate cancer surgeries for surgeons to become proficient at the RALP procedure and be able to remove the cancerous prostate consistently with its edges clear of cancer.

  • Dutasteride helps slow early-stage prostate cancer growth: A new study has shown that a drug commonly used to treat men with an enlarged prostate gland dutasteride (Avodart) may also slow the growth of early-stage prostate cancer among men participating in "active surveillance" of their disease.

"While the use of PSA in determining which men should have biopsies for suspected prostate cancer has sometimes been controversial, the results of a study presented today provide important new insights on the value of PSA in helping practitioners make treatment decisions," said Nicholas J. Vogelzang, MD, Chair and Medical Director of the Developmental Therapeutics Committee of US Oncology, who moderated today's presscast. "Other significant studies presented today show the potential of an already commonly used prostate drug to slow cancer growth. And a second evaluates the expertise required to carry out often difficult surgical procedures."

Genitourinary cancers include those of the prostate, kidney, bladder and testis, as well as less common cancers such as those of the penis, ureters and other urinary organs. In 2010, more than 358,000 people in the United States were diagnosed with genitourinary cancers and more than 61,000 died of these diseases. The most common genitourinary cancer is prostate cancer, which was diagnosed in nearly 218,000 men in the United States in 2010 and claimed more than 32,000 lives.*


'/>"/>

Contact: Kelly Powell
kelly.powell@asco.org
571-483-1365
American Society of Clinical Oncology
Source:Eurekalert

Related medicine news :

1. Embedded Mobile & M2M Device revenues to Rise to Almost $19 Billion Globally by 2014, Says Juniper Research
2. 2010 HSR Impact Award recognizes surgical safety research
3. MSU launches first anti-counterfeiting research program
4. Researchers map all the fragile sites of the yeast Saccharomyces cerevisiaes genome
5. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
6. Researchers discover new way to kill pediatric brain tumors
7. Family Research Council: Planned Parenthood Report Oversexualizes Ten-Year-Olds, Undermines Parental Authority
8. Michael J. Fox Foundation Awards $1 Million to Drive Critical New Research Tools and Technologies in Parkinsons Drug Development
9. Luth Researchs IndicatorEDG(TM) Study Finds Americans Hopes of Achieving Their Dreams Are Fading
10. International Diabetes Federation awards $2 million to 9 global diabetes research projects
11. Gladstones Robert Mahley to receive Research!America advocacy award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Braunfels, TX (PRWEB) , ... March 23, 2017 , ... ... new clinic, located at 960 Gruene Road in Building 2. The clinic is the ... Dr. Andrew Bennett, PT, says opening the company’s second New Braunfels location brings things ...
(Date:3/23/2017)... ... ... The IoT (Internet of Things) is revolutionizing the way the world operates. ... and individual consumers alike. Laboratories can maximize their profit margin by increasing throughput. ... trillion to $11 trillion dollars by the year 2025. McKinsey expects the IoT to ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... 82% of adults are unaware of the ... do not brush their teeth the minimum two times a day that dentists recommend. The ... missing 51 million hours of school and adults missing 164 million hours of work each ...
(Date:3/23/2017)... ... ... March is National Kidney Month – the perfect time to pause and ... health. Every day, two kidneys filter about 120 to 150 quarts of blood. Put ... waste, regulating fluid levels and blood pressure, supporting bone health and promoting red blood ...
(Date:3/23/2017)... ... March 23, 2017 , ... The StayWell Company announced today ... accreditation covers StayWell’s asthma, coronary artery disease, congestive heart failure, chronic obstructive pulmonary ... have excellent programs for the delivery and improvement of disease management and that ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... DUBLIN , Mar 23, 2017 Research ... Electrophoresis Market 2017-2021" report to their offering. ... The global capillary electrophoresis market ... The report, Global Capillary Electrophoresis Market 2017-2021, has ... industry experts. The report covers the market landscape and its growth ...
(Date:3/23/2017)... -- CENTRO DE IMAGEM DIAGNOSTICOS S.A. (" Company "), ... 6,404/76 and Instruction 358/02 of the Brazilian Securities and ... market in general that it entered yesterday, as a ... Imagem Ltda. (" CDI "), into an agreement for ... (" Partnership " and " Acquisition "). ...
(Date:3/23/2017)... -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company ... unmet medical needs in rare diseases, today announced that ... on Monday, April 3 during ENDO 2017, the annual ... Florida , to discuss new data regarding its ... PTH and TransCon CNP). Ascendis is presenting ...
Breaking Medicine Technology: